Skip to main content
Homepage of ProQR
  • We are ProQR
    • About ProQR Therapeutics
    • Founding story
    • Leadership
    • Contact
    • Events
  • Patients
    • Biliary atresia
    • Hurler syndrome
  • Pipeline
    • Pipeline overview
    • AX-0810/AX-0811 cholestatic diseases (NTCP)
    • AX-0422 Hurler syndrome (IDUA)
  • Science
    • Science overview
    • Axiomer technology
      • How Axiomer and ADAR work
    • RNA therapy
    • Presentations & Publications
    • Partnerships
  • News
    • Press Releases
    • Blogs, stories and news
    • Email alerts
  • Careers
    • Working at ProQR
    • Vacancies
    • Recruitment experience
    • ProQRian Profiles
  • Investors & Media
    • Investors & Media overview
    • Press Releases
    • Events
    • Corporate presentation
    • Corporate governance
    • Financials and filings
    • Stock info
    • Analyst coverage
    • Contact us
  1. Home
Listen

Annual Report 2025

Publication

Published on March 16, 2026

Link Download

Share page

  • Facebook
  • Linkedin
  • Twitter
  • Whatsapp
  • Email

Related publications

  • Full field stimulus testing (FST) to assess sepofarsen patient response in Leber congenital amaurosis type 10

    AAO 2020 poster by Allen Ho et al. Recognized with best poster award. Data show that FST seems a more sensitive method in patients with severely impaired vision.

    Date: November 13, 2020

    Author(s): Ho A, Cideciyan AV, et al.

    ePoster

  • Results of a phase 1b/2 trial of intravitreal (IVT) sepofarsen (QR-110) antisense oligonucleotide in Leber congenital amaurosis 10 (LCA10) due to p.Cys998X mutation in the CEP290 gene

    AAO 2020 poster by Stephen Russel et al. Recognized with best poster award. Sepofarsen had a manageable safety profile and showed improvement in mean visual acuity, and full-field stimulus testing.

    Date: November 13, 2020

    Author(s): Russell SR, Drack AV, et al.

    ePoster

  • Results of a phase 1b/2 trial of intravitreal (IVT) sepofarsen (QR-110) antisense oligonucleotide in Leber congenital amaurosis 10 (LCA10) due to p.Cys998X mutation in the CEP290 gene

    ARVO 2020 clinical trial results presentation by Stephen Russel et al. Sepofarsen had a manageable safety profile and showed improvement in mean visual acuity, and full-field stimulus testing.

    Date: June 17, 2020

    Author(s): Russell SR, Drack AV, et al.

    Presentation

  • ARVO (2021) Russell SR et al., Safety and efficacy of sepofarsen in the second treated eye in a Ph1b/2 extension trial in Leber Congenital Amaurosis type 10 (LCA10)

    ARVO 2021 presentation by Stephen R. Russell from Iowa University on the Safety and efficacy of sepofarsen in the second treated eye in a Ph1b/2 extension trial in CEP290 mediated Leber Congenital Amaurosis type 10.

    Date: May 06, 2021

    Presentation
Internal link More publications

Follow us

  • Twitter (opens in new window)
  • Facebook (opens in new window)
  • Instagram (opens in new window)
  • Linkedin (opens in new window)
  • Youtube (opens in new window)
  • Soundcloud (opens in new window)
  • Contact
  • Disclaimer
  • Privacy
  • Sitemap

© 2026 ProQR Therapeutics. All Rights Reserved.

Back to top